Back British biotech by improving the clinical trials process
Andrew Boyle, CEO of LGB & Co. Limited, wrote an article for Pharmiweb on how to improve the British biotech sector.
The UK has a thriving life sciences sector. With three of the world’s top ten universities in the field – Oxford, Cambridge and UCL – plus prominent bioscience clusters in other British university cities such as Nottingham and Cardiff, UK research accounts for 12% of all life sciences academic citations worldwide (and nearly a fifth of the top 1% of these).
To read the full article, please click here.